- UAA Congress 2025

Back

Final Presentation Format

Moderated Poster Abstract

Eposter Presentation

Eposter in PDF Format

https://storage.unitedwebnetwork.com/files/1237/fa9bf8e90e82de18c5f24e8b1412f3c1.pdf

Accept format: PDF. The file size should not be more than 5MB

Eposter in Image Format

https://storage.unitedwebnetwork.com/files/1237/d970e74392fda2e7ee927c63f16bcb92.jpg

Accept format: PNG/JPG/WEBP. The file size should not be more than 2MB

Abstract

Abstract Title

Is More Always Better? Evaluating the Addition of TRUS Biopsy to Targeted and Systematic Fusion Prostate Biopsy

Presentation Type

Moderated Poster Abstract

Manuscript Type

Clinical Research

Abstract Category *

Oncology: Prostate

Author's Information

Number of Authors (including submitting/presenting author) *

No more than 10 authors can be listed (as per the Good Publication Practice (GPP) Guidelines).
Please ensure the authors are listed in the right order.

Co-author 1

Chien Hsiang Huang jimmyhuang820819@gmail.com Divisions of Urology, Department of Surgery, Kaohsiung Veterans General Hospital Divisions of Urology, Department of Surgery, Kaohsiung Veterans General Hospital Kaohsiung Taiwan *

Co-author 2

Wei-Ting Kuo jimmyhuang820819@gmail.com Divisions of Urology, Department of Surgery, Kaohsiung Veterans General Hospital Divisions of Urology, Department of Surgery, Kaohsiung Veterans General Hospital Kaohsiung Taiwan -

Co-author 3

Chia-Cheng Yu jimmyhuang820819@gmail.com Divisions of Urology, Department of Surgery, Kaohsiung Veterans General Hospital Divisions of Urology, Department of Surgery, Kaohsiung Veterans General Hospital Kaohsiung Taiwan -

Co-author 4

Co-author 5

Co-author 6

Co-author 7

Co-author 8

Co-author 9

Co-author 10

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15

Co-author 16

Co-author 17

Co-author 18

Co-author 19

Co-author 20

Abstract Content

Introduction

Targeted and systematic fusion prostate biopsy has become increasingly popular due to its superior detection of clinically significant prostate cancer (csPCa) compared to conventional TRUS-guided biopsy. This study investigates whether adding a conventional TRUS biopsy to targeted and systematic fusion biopsy further improves the csPCa detection rate.

Materials and Methods

In 2024, a total of 153 patients at our institution underwent multiparametric MRI (mpMRI), followed by targeted and systematic fusion prostate biopsy. All mpMRIs were performed using a single 3T scanner and interpreted by one experienced radiologist. Subsequently, all patients also received an additional conventional TRUS-guided biopsy. We compared the detection and upgrade rates between targeted/systematic fusion biopsy alone and the combined approach with added TRUS biopsy.

Results

Among the 153 patients, 18 had cancer detected only through conventional TRUS biopsy. However, these cases did not contribute to an increased detection rate of clinically significant prostate cancer when compared with the results of fusion biopsy alone. Thus, the addition of TRUS biopsy provided no significant benefit in detecting or upgrading csPCa.

Conclusions

More is not always better. Targeted and systematic fusion biopsy alone offers high detection rates for clinically significant prostate cancer. The routine addition of conventional TRUS biopsy does not improve diagnostic yield and may be unnecessary.

Keywords

Clinically significant prostate cancer, TRUS biopsy, Targeted, and systematic fusion prostate biopsy

Figure 1

Figure 1 Caption

Figure 2

Figure 2 Caption

Figure 3

Figure 3 Caption

Figure 4

Figure 4 Caption

Figure 5

Figure 5 Caption

Presentation Order